{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:19:27Z","timestamp":1773163167650,"version":"3.50.1"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Prostate specific membrane antigen (<jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>) positron emission tomography (<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>) is an emerging imaging modality in prostate cancer. However, <jats:sup>68<\/jats:sup>Ga\u2010<jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> may also have diagnostic utility in the setting of renal cell carcinoma (<jats:styled-content style=\"fixed-case\">RCC<\/jats:styled-content>). We investigate the differential role of <jats:sup>18<\/jats:sup>F\u2010fluorodeoxyglucose (<jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>) and <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> scanning in patients with oligometastatic <jats:styled-content style=\"fixed-case\">RCC<\/jats:styled-content>. In particular, we focus on the utility of <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> for diagnostic evaluation of isolated or limited metastases planned for local surgery or radiation, as well as the potential utility of <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> for therapeutic response assessment in patients receiving stereotactic ablative body radiotherapy (<jats:styled-content style=\"fixed-case\">SABR<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We present a retrospective series of eight patients in which comparative imaging modalities are evaluated against <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> scanning. <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> scans were performed prior to definitive treatment (either surgery or <jats:styled-content style=\"fixed-case\">SABR<\/jats:styled-content>) of limited recurrent disease. Response assessment after <jats:styled-content style=\"fixed-case\">SABR<\/jats:styled-content> was performed with both <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> imaging modalities at multiple time points in a subset of four patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prostate specific membrane antigen uptake is typically more intense than <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">RCC<\/jats:styled-content>. In all but two cases, one of which was papillary carcinoma, <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content> are concordant for detection of sites of disease. We demonstrate for the first time the differential kinetics of post\u2010treatment response using <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>, with a more rapid metabolic response observed on <jats:styled-content style=\"fixed-case\">FDG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>. Both modalities demonstrate response earlier than morphological appearances on <jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">MRI<\/jats:styled-content> imaging.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our series suggests that <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content> shows early promise as a diagnostic and therapeutic response assessment tool in patients with metastatic <jats:styled-content style=\"fixed-case\">RCC<\/jats:styled-content> receiving definitive local therapies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1754-9485.12590","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T06:35:14Z","timestamp":1485239714000},"page":"372-378","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Utility of <sup>68<\/sup>Ga prostate specific membrane antigen \u2013 positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma"],"prefix":"10.1111","volume":"61","author":[{"given":"Shankar","family":"Siva","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology and Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Callahan","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology and Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pryor","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Princess Alexandra Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarad","family":"Martin","sequence":"additional","affiliation":[{"name":"Calvary Mater Hospital Waratah New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S","family":"Hofman","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology and Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.03.025"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.40"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001128"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2766-y"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-015-1017-z"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.939298"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2012.0042"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc700341x"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2013-0067"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<344::AID-CNCR19>3.0.CO;2-T"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1027409"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1754-9485.12590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.12590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:09:22Z","timestamp":1696248562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.12590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/1754-9485.12590"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.12590","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"value":"1754-9477","type":"print"},{"value":"1754-9485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,24]]},"assertion":[{"value":"2016-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}